Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Benzenesulfonamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 18/20 | 0.94 |
| ▸ | HTR6 known ✓ | P50406 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 16/20 | 0.94 |
| ▸ | CA12 | O43570 | 14/20 | 0.94 |
| ▸ | CA9 | Q16790 | 14/20 | 0.94 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 0.94 |
| ▸ | CA6 | P23280 | 5/20 | 0.94 |
| ▸ | CA5A | P35218 | 5/20 | 0.94 |
| ▸ | CA7 | P43166 | 5/20 | 0.94 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.94 |
| ▸ | CA4 | P22748 | 4/20 | 0.94 |
| ▸ | CA3 | P07451 | 4/20 | 0.94 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.94 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.94 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | AGO2 | Q9UKV8 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzenesulfonamide SCHEMBL6999082 | 1.00 | CA2 (0.94) | CA2CA1CA12CA9CA14 | |
| Benzenesulfonamide SCHEMBL27937101 | 0.97 | CA2 (0.89) | CA2CA1CA12CA9CA14 | |
| Benzenesulfonamide SCHEMBL28257999 | 0.97 | CA2 (1.00) | CA2CA1CA12CA9CA14 | |
| Benzenesulfonamide SCHEMBL729 | 0.97 | CA2 (1.00) | CA2CA1CA12CA9CA14 | |
| Benzenesulfonamide SCHEMBL6868390 | 0.97 | CA2 (1.00) | CA2CA1CA12CA9CA14 | |
| SCHEMBL19479299 | 0.97 | CA2 (1.00) | CA2CA1CA12CA9CA14 | |
| Benzenesulfonamide SCHEMBL1332409 | 0.97 | CA2 (1.00) | CA2CA1CA12CA9CA14 | |
| Benzenesulfonamide SCHEMBL29825137 | 0.97 | CA2 (1.00) | CA2CA1CA12CA9CA14 | |
| Benzenesulfonamide SCHEMBL1009443 | 0.94 | CA2 (0.94) | CA2CA1CA12CA9CA14 | |
| Benzenesulfonamide SCHEMBL7517039 | 0.94 | CA2 (0.94) | CA2CA1CA12CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 237 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116284022-B | Self-blinking fluorescent dye, synthesis and application thereof | 中国科学院大连化学物理研究所 | 2024-09-24 | — | — | CN | claimed |
| CN-116284022-A | Self-blinking fluorescent dye, synthesis and application thereof | 中国科学院大连化学物理研究所 | 2023-06-23 | — | — | CN | claimed |
| EP-2941424-A1 | 1,2,3-TRIAZOLE-4-AMINE DERIVATIVES FOR THE TREATMENT OF SIGMA RECEPTOR RELATED DISEASES AND DISORDERS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2015-11-11 | — | — | EP | claimed |
| CN-104177294-A | Preparation method of celecoxib | QILU TIANHE PHARMACEUTICAL CO LTD | 2014-12-03 | — | — | CN | claimed |
| WO-2014106622-A1 | 1,2,3-TRIAZOLE-4-AMINE DERIVATIVES FOR THE TREATMENT OF SIGMA RECEPTOR RELATED DISEASES AND DISORDERS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2014-07-10 | — | — | WO | claimed |
| CN-103724268-A | Celecoxib preparation method | CHENGDU GUOHONG PHARMACEUTICAL CO LTD | 2014-04-16 | — | — | CN | claimed |
| CN-103524416-A | Novel crystal form A of celecoxib and preparation method thereof | WATERSTONE PHARMACEUTICALS INC | 2014-01-22 | — | — | CN | claimed |
| CN-103224488-A | Heterocyclic compound or salt thereof | OTSUKA PHARMA CO LTD | 2013-07-31 | — | — | CN | claimed |
| CN-103044329-A | Preparation method of high-yield and high-purity celecoxib | QIHE CHENGHUI FINE CHEMICAL CO LTD | 2013-04-17 | — | — | CN | claimed |
| CN-102746232-A | Preparation method of celecoxib impurity | SHIJIAZHUANG PHARM GROUP OUYI | 2012-10-24 | — | — | CN | claimed |
| CN-1531531-A | Novel arylsulfonamide compounds for the treatment of obesity, type II diabetes and CNS-disorders | �Ȱ�ά����ķ�ɷݹ�˾ | 2004-09-22 | — | — | CN | claimed |
| CN-1522245-A | Substituted sulfonamide compounds, process for their preparation and their use as medicaments for the treatment of CNS disorders, obesity and type II diabetes | �Ȱ�ά����ķ�ɷݹ�˾ | 2004-08-18 | — | — | CN | claimed |
| EP-1406884-A1 | ARYLSUSFONAMIDE COMPOUNDS FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS-DISORDERS | BIOVITRUM AB (SE) | 2004-04-14 | — | — | EP | claimed |
| CN-1438997-A | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type I | BIOVITRUM AB (SE) | 2003-08-27 | — | — | CN | claimed |
| WO-2002092585-A1 | NOVEL, ARYLSUSFONAMIDE COMPOUNDS FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS-DISORDERS | BIOVITRUM AB (SE) | 2002-11-21 | — | — | WO | claimed |
| EP-0859607-A4 | GUANIDINO PROTEASE INHIBITORS | DIMENSIONAL PHARM INC (US) | 1999-05-06 | — | — | EP | claimed |
| EP-0859607-A1 | GUANIDINO PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1998-08-26 | — | — | EP | claimed |
| WO-1997011693-A1 | GUANIDINO PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1997-04-03 | — | — | WO | claimed |
| EP-0682663-A1 | 4-HYDROXY-BENZOPYRAN-2-ONES AND 4-HYDROXY-CYCLOALKYL B]PYRAN-2-ONES USEFUL TO TREAT RETROVIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 1995-11-22 | — | — | EP | claimed |
| CN-1090887-A | The high-sudsers composition that contains specially selected soap | PROCTER & GAMBLE (US) | 1994-08-17 | — | — | CN | claimed |